NCT03080987View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-64179375 0.3 mg/kg

JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.

DRUG

JNJ-64179375 1.0 mg/kg

JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

DRUG

JNJ-64179375 2.5 mg/kg

JNJ-64179375 2.5 mg/kg IV infusion on Day 1.

OTHER

Placebo

Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

DRUG

JNJ-64179375 (Dose to be Determined)

JNJ-64179375 IV infusion (Dose to be determined).

Trial Locations (2)

812-0025

Souseikai Hakata Clinic, Fukuoka

NW10 7EW

Hammersmith Medicines Research Ltd, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03080987 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter